Search

New data suggests that new treatment options may be on the horizon for patients with liver cancer. Liver cancer, particularly hepatocellular carcinoma (HCC), has low survival rates with current available treatments. However, recent clinical trials have shown potential improvements in progression-free survival (PFS) and overall survival (OS) with the combination of the VEGFR2-targeted inhibitor rivoceranib and the PD-1 inhibitor camrelizumab for patients with unresectable HCC. Additionally, there are promising results in the treatment of HER2-positive biliary tract cancers with novel targeted anti-HER2 drugs such as zanidatamab and tucatinib. These findings offer hope for expanding treatment options and improving outcomes for patients with liver cancer. [Extracted from the article]

The article discusses research by J. Valle et al published in the "New England Journal Medicine," which indicated that biliary tract cancer patient who received a combination treatment comprised of cisplatin and gemcitabine were 36% less likely to die and 37% less likely to progress.

The article focuses on a phase-3 trial which revealed that the combined use of gemcitabine plus cisplatin to treat patients with advanced or metastatic biliary tract cancer reduced the risk of death by 32% and the risk of progression by 30% compared with treatment with gemcitabine alone, presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida on May 29 to June 2.